- Home
- WT vs ETNB Comparison
WT vs ETNB Comparison
Compare WT & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WT
- ETNB
- Stock Information
- Founded
- WT 1985
- ETNB 2018
- Country
- WT United States
- ETNB United States
- Employees
- WT N/A
- ETNB N/A
- Industry
- WT Investment Bankers/Brokers/Service
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- WT Finance
- ETNB Health Care
- Exchange
- WT Nasdaq
- ETNB Nasdaq
- Market Cap
- WT 1.5B
- ETNB 1.5B
- IPO Year
- WT N/A
- ETNB 2019
- Fundamental
- Price
- WT $13.71
- ETNB $9.98
- Analyst Decision
- WT Buy
- ETNB Strong Buy
- Analyst Count
- WT 7
- ETNB 8
- Target Price
- WT $12.99
- ETNB $26.43
- AVG Volume (30 Days)
- WT 3.1M
- ETNB 1.5M
- Earning Date
- WT 08-01-2025
- ETNB 08-04-2025
- Dividend Yield
- WT 0.88%
- ETNB N/A
- EPS Growth
- WT N/A
- ETNB N/A
- EPS
- WT 0.37
- ETNB N/A
- Revenue
- WT $438,981,000.00
- ETNB N/A
- Revenue This Year
- WT $10.20
- ETNB N/A
- Revenue Next Year
- WT $8.52
- ETNB N/A
- P/E Ratio
- WT $37.33
- ETNB N/A
- Revenue Growth
- WT 20.66
- ETNB N/A
- 52 Week Low
- WT $7.47
- ETNB $4.16
- 52 Week High
- WT $13.73
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- WT 85.05
- ETNB 46.96
- Support Level
- WT $12.90
- ETNB $9.82
- Resistance Level
- WT $12.81
- ETNB $10.48
- Average True Range (ATR)
- WT 0.27
- ETNB 0.49
- MACD
- WT 0.04
- ETNB -0.11
- Stochastic Oscillator
- WT 98.74
- ETNB 10.34
About WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. It offers a broad range of ETFs and exchange-traded products (ETPs). The firm also engages in developing next-generation digital products and structures, including digital funds and tokenized assets, as well as its blockchain-native digital wallet, WisdomTree Prime. The Company conducts business under a single operating segment as an ETP sponsor and asset manager.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).